InsidersTradesSigma
Total declarations
Companies
▲ Purchases (0 ops.)
▼ Sales (0 ops.)
Insider track record
ExecutiveDisclosed buys
0
Disclosed sells
0
T+90 hit rate
50%
T+90 mean return
-4.7%
Across 4 buy signals with a settled T+90 return. Return basis: close on the day after publication.
Signal history
Browse the detailed record of transactions filed by Chesworth Richard, Directeur Scientifique. Director active across 2 companies, notably Kymera Therapeutics, Inc.. In total, 4 filings have been published. Activity tracked since 17 August 2021. The latest transaction was disclosed on 27 August 2021 (Levée d'options). Regulator: SEC (Form 4). All data is accessible without signup.
Declarations4 total
33,779 shares@ US$20.0038.4% of flowCommon StockSEC:0001209191-21-053642
33,779 shares@ US$20.000.0092% mcap38.4% of flowCommon StockSEC:0001209191-21-053642:0
54,000 shares@ US$20.0061.6% of flowCommon StockSEC:0000899243-21-033638
54,000 shares@ US$20.000.015% mcap61.6% of flowCommon StockSEC:0000899243-21-033638:0
4 of 4 declarations
About Chesworth Richard
Chesworth Richard is the Chief Scientific Officer of Kymera Therapeutics, Inc. In this role, he oversees the company's scientific research and development. His expertise is crucial for innovation and the development of new therapies within Kymera Therapeutics, Inc.
